---

Immunotherapy for head and neck cancer – The current scenario

Full Text PDF

---

Review Article

Author Details : Abhimanyu Kadapathri*, Shashank Chaudhary, Linu Thomas, Ashok Balan, Sumanth K R

Volume : 5, Issue : 4, Year : 2020

Article Page : 146-150

https://doi.org/10.18231/j.ijcaap.2020.030

Suggest article by email

Get Permission

Abstract

Anticancer immunity modulation is the current standpoint of research and has revolutionized the standard of care of platinum refractory recurrent/metastatic head and neck carcinoma of squamous cell origin (R/M HNSCC). Checkpoint inhibitors are targeted at PD-1/ PD-L1 axis, which is involved in the genesis, maintenance and progression of HNSCC. Head and neck cancer has an immunosuppressive character and a high inflammatory response component in the tumor microenvironment. The clinical settings in which these agents are highly useful are in study all around the globe. We discuss the current up to date clinical trial results and the future prospective of cancer immunotherapy in the field of HNSCC.

Keywords: Immunotherapy, Head and neck cancer, Metastatic cancer, Squamous cell carcinoma.

How to cite : Kadapathri A, Chaudhary S, Thomas L, Balan A, Sumanth K R, Immunotherapy for head and neck cancer – The current scenario. IP Int J Compr Adv Pharmacol 2020;5(4):146-150

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.